- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05223569
Home Monitoring of Diabetic Macular Edema
March 30, 2023 updated by: Zhongshan Ophthalmic Center, Sun Yat-sen University
Diabetic macular edema (DME) is part of diabetic retinopathy (DR) and a leading cause of central visual loss in people with diabetes .
Most patients require pharmacological inhibition using anti-vascular endothelial growth factor (VEGF) agents with multiple monitoring visits that include optical coherence tomography (OCT), visual acuity test, and multiple injections.The substantial visit frequency puts pressure on ophthalmic clinics, and can impose a tremendous burden on both patients and their caregivers.
Therefore, self-service examination instruments that can be portable and fast-moving become the key for realizing tele-medicine.
Recently, the investigators have developed a portable, self-administrated home OCT machine, which is designed for home-based OCT scanning and monitoring for patients with retinal diseases including DME, age related macular degeneration (AMD) and choroidal neovascularization (CNV) that require multiple anti-VEGF injections.
The investigators have confirmed its image quality and validated the retinal thickness measurements obtained from this device by comparing with hospital OCT (staff-administrated and clinic-based).In this study, the investigators will conduct a randomized clinical trial (RCT) to compare the efficacy and cost-effectiveness of a home OCT monitoring model versus standard hospital care model for patients with diabetic macular edema who need anti-VEGF injections.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shida Chen, MD
- Phone Number: 13760849121
- Email: chenshd3@mail.sysu.edu.cn
Study Contact Backup
- Name: Yingfeng Zheng, MD
- Phone Number: 13922286455
- Email: zhyfeng@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Zhongshan Ophthalmic Center
-
Contact:
- yingfeng Zheng
- Phone Number: +862066683995
- Email: zhyfeng@mail.sysu.edu.cn
-
Principal Investigator:
- Yingfeng Zheng
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 years;
Diagnosis of diabetic macular edema:
- Type 1 or type 2 diabetes mellitus;
- Center-involved macular edema;
- Willing to receive anti-VEGF treatment;
- Media clarity, pupillary dilation, and individual cooperation sufficient for adequate OCT examination;
- Able to operate self-administratedhome OCT by themselves or with the help of family;
- Travel time from home to hospital: within 2 hours driving.
- Able and willing to provide informed consent.
Exclusion Criteria:
- History of systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization. (These drugs should not be used during the study);
- History of corticosteroid treatment (intravitreal or peribulbar) at any time in the past 4 months;
- History of macular laser photocoagulation in the past 4 months;
- Macular edema due to reasons other than diabetes;
- Coexisting ocular diseases that might alter visual acuity during the course of the study, such as retinal vein or artery occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.);
- Hypertension (systolic blood pressure (BP) above 180 or diastolic BP above 110);
- History of myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization;
- Pregnant or lactating;
- Currently participating in other clinical trials;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Hospital-based monitoring with a staff-administrated OCT
Participants will be instructed to come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators every month.
|
Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
|
Experimental: Home OCT monitoring model
Participants will receive a home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester. For each home service, participants will undergo the following:
|
A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in visual acuity
Time Frame: 12 weeks
|
Changes in visual acuity from baseline to 12 weeks adjusted for baseline visual acuity
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The costs of treatment
Time Frame: 12 weeks
|
The Cost-effectiveness between the two monitoring models
|
12 weeks
|
Number of intravitreal injections
Time Frame: 12 weeks
|
The number of intravitreal injections given per group
|
12 weeks
|
Gains or losses in visual acuity
Time Frame: 12 weeks
|
The proportion of eyes with two- and three-line gains or losses in visual acuity
|
12 weeks
|
Central subfield thickness change as measured by optical coherence tomography
Time Frame: 12 weeks
|
central subfield thickness and retinal volume as measured by OCT after 12 weeks
|
12 weeks
|
Number of visits
Time Frame: 12 weeks
|
The number of visits during the study
|
12 weeks
|
Changes in visual acuity after 24 weeks
Time Frame: 24 weeks
|
Changes in visual acuity from baseline to 24 weeks adjusted for baseline visual acuity
|
24 weeks
|
Changes in visual acuity after 48 weeks
Time Frame: 48 weeks
|
Changes in visual acuity from baseline to 48 weeks adjusted for baseline visual acuity
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Han X, Scheetz J, Keel S, Liao C, Liu C, Jiang Y, Muller A, Meng W, He M. Development and Validation of a Smartphone-Based Visual Acuity Test (Vision at Home). Transl Vis Sci Technol. 2019 Aug 19;8(4):27. doi: 10.1167/tvst.8.4.27. eCollection 2019 Jul.
- Maloca P, Hasler PW, Barthelmes D, Arnold P, Matthias M, Scholl HPN, Gerding H, Garweg J, Heeren T, Balaskas K, de Carvalho JER, Egan C, Tufail A, Zweifel SA. Safety and Feasibility of a Novel Sparse Optical Coherence Tomography Device for Patient-Delivered Retina Home Monitoring. Transl Vis Sci Technol. 2018 Jul 24;7(4):8. doi: 10.1167/tvst.7.4.8. eCollection 2018 Jul.
- Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, Kreutzer T, Schiefelbein J, Rottmann M, Priglinger S, KortUEm KU. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE. Retina. 2018 Dec;38(12):2293-2300. doi: 10.1097/IAE.0000000000001892.
- Jusufbegovic D, Mugavin MO, Schaal S. EVOLUTION OF CONTROLLING DIABETIC RETINOPATHY: Changing Trends in the Management of Diabetic Macular Edema at a Single Institution Over the Past Decade. Retina. 2015 May;35(5):929-34. doi: 10.1097/IAE.0000000000000438.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 3, 2022
Primary Completion (Anticipated)
December 12, 2023
Study Completion (Anticipated)
June 1, 2024
Study Registration Dates
First Submitted
January 22, 2022
First Submitted That Met QC Criteria
February 3, 2022
First Posted (Actual)
February 4, 2022
Study Record Updates
Last Update Posted (Actual)
April 4, 2023
Last Update Submitted That Met QC Criteria
March 30, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021KYPJ099
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Edema Due to Diabetes Mellitus
-
Sudhalkar Eye HospitalNot yet recruitingClinically Significant Macular Edema Due to Diabetes MellitusGermany
-
Second Affiliated Hospital, School of Medicine,...RecruitingVitreous Hemorrhage | Macular Edema Due to Diabetes MellitusChina
-
IRCCS MultimedicaAbbVieRecruitingDiabetic Macular Edema | Retinal Vein Occlusion | Macular Edema Due to Diabetes MellitusItaly
-
Uptown Eye SpecialistsUnknownDiabetic Retinopathy | Cataract | Macular Edema Due to Diabetes MellitusCanada
-
The New Model of Care, Hail Health ClusterHealth Holding Company, Hail Health ClusterNot yet recruitingArtificial Intelegence | Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus | Macular Edema Due to Type 2 Diabetes Mellitus
-
Novartis PharmaceuticalsWithdrawnVisual Impairment Due to Diabetic Macular EdemaGermany
-
Novartis PharmaceuticalsCompletedNeovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNVGermany
-
Novartis PharmaceuticalsWithdrawnVisual Impairment Due to Diabetic Macular Edema
-
Kyoto University, Graduate School of MedicineNovartisUnknown
-
Asociación para Evitar la Ceguera en MéxicoUnknownDiabetic Macular Edema | Diabetes Mellitus Type 2Mexico
Clinical Trials on Hospital-based monitoring with a staff-administrated OCT
-
Singapore General HospitalRootally AI PTE LTDNot yet recruiting